Implantable Loop Recorder in Unexplained Falls: Cost-Effectiveness Analysis
Unexplained falls in older adults can signal intermittent bradyarrhythmia, paroxysmal atrioventricular block, supraventricular tachycardia, or ventricular arrhythmia. Yet the event is often unwitnessed, the patient may have amnesia, and an injury can obscure the preceding symptom. As a result, a potentially cardiovascular episode is frequently classified as a mechanical fall, dizziness, or frailty-related instability.
An implantable loop recorder (ILR), also called an insertable cardiac monitor, offers prolonged rhythm surveillance when routine electrocardiography and short-term ambulatory monitoring are unrevealing. Its economic value depends on more than the device price. The relevant question is whether earlier rhythm diagnosis prevents recurrent falls, hospital admissions, injuries, unnecessary testing, and inappropriate medication while leading to treatments that improve outcomes.
A cost-effectiveness analysis therefore needs to connect diagnostic yield with clinical consequences. It should account for the characteristics of the population, the comparator strategy, the time horizon, healthcare prices, quality-adjusted life-years (QALYs), and the downstream use of pacemakers, ablation, anticoagulation, or other therapies.
Why Falls Require An Arrhythmia-Focused Assessment
A fall is not a diagnosis. In older patients, transient loss of consciousness may be denied because the episode was brief or unwitnessed. Post-event confusion, fear of recurrent injury, and cognitive impairment can further limit the history. A careful assessment should distinguish accidental falls from syncope, near-syncope, unexplained collapse, and falls associated with palpitations or exertion.
The pretest probability of an arrhythmic cause is central to the economic case for an ILR. The device is unlikely to be efficient for every person with a single low-risk fall and a clear environmental trigger. Its value rises when episodes recur, injuries are serious, baseline conduction disease is present, structural heart disease increases risk, or conventional monitoring has failed to capture a suspected intermittent rhythm disturbance.
An ILR can monitor for several years, depending on the device and battery life, without requiring patient activation during a sudden event. This makes it particularly useful when symptoms are infrequent. However, implantation is an invasive procedure, and an incidental rhythm finding may create additional testing or treatment without improving health. Economic models must therefore distinguish clinically actionable diagnoses from any detected arrhythmia.
How The Economic Evaluation Should Be Built
The most informative model usually compares an ILR-based pathway with usual care, external loop recording, Holter monitoring, patch monitoring, or repeated emergency evaluation. A decision tree can represent the initial diagnostic period, while a Markov model or patient-level simulation can follow recurrent falls, rhythm diagnoses, device implantation, treatment, complications, and death over a longer horizon.
Costs should include implantation, device interrogation, remote monitoring, explantation when required, specialist visits, diagnostic tests, emergency transport, hospital stays, injury management, rehabilitation, and treatment-related follow-up. For example, a pacemaker may generate an immediate cost but reduce future admissions caused by bradyarrhythmic syncope. Similarly, a diagnosis of atrial fibrillation may lead to anticoagulation and stroke prevention, with both benefits and bleeding risks represented.
The model should report incremental cost-effectiveness ratios and, where appropriate, incremental cost per QALY gained. A payer perspective may exclude informal care and productivity losses, whereas a societal perspective can include them. Because unexplained falls disproportionately affect older adults, investigators should state whether nursing care, caregiver time, transportation, and long-term disability are included.
| Evaluation component | Questions that materially affect value |
|---|---|
| Population | How likely is an arrhythmic cause, and how often do falls recur? |
| Comparator | Is the alternative usual care, external monitoring, or repeated hospital assessment? |
| Time horizon | Does the analysis capture later falls, injuries, pacemaker therapy, and stroke prevention? |
| Outcomes | Are actionable diagnoses, QALYs, injuries, admissions, and mortality measured? |
| Costs | Are implantation, monitoring, treatment, complications, and follow-up included? |
| Uncertainty | How do results change with diagnostic yield, device price, and treatment uptake? |
Clinical Yield And Downstream Treatment
The principal economic benefit of an ILR comes from a diagnosis that changes management. A recorded pause or high-grade atrioventricular block may lead to permanent pacing and reduce future syncope. Detection of atrial fibrillation can trigger an individualized stroke-prevention discussion. Identification of a tachyarrhythmia may support medication, electrophysiology referral, or catheter ablation.
Diagnostic yield should not be interpreted in isolation. A high percentage of rhythm abnormalities may reflect benign ectopy or episodes unrelated to the fall. Cost-effectiveness improves when the study defines an event criterion in advance, links the rhythm to symptoms or injury, and measures whether clinicians acted on the finding. False attribution can expose patients to unnecessary procedures and distort the apparent value of prolonged monitoring.
The broader electrophysiology pathway also matters. For example, an identified atrial tachycardia may require a targeted intervention, and readers can place such decisions in the context of radiofrequency ablation experience. In patients with cardiomyopathy, a ventricular arrhythmia detected during monitoring may prompt a substantially different risk assessment; the challenges described in ventricular tachycardia ablation illustrate why the downstream pathway can be resource-intensive and clinically consequential.
Factors That Shift Cost-Effectiveness
The expected value of an ILR increases as the probability of an intermittent arrhythmia rises. Recurrent unexplained falls, abnormal ECG findings, bifascicular block, unexplained injury, structural heart disease, and a history suggestive of syncope can all strengthen the case. Conversely, a clearly witnessed trip, a stable alternative diagnosis, or a low likelihood of follow-up may reduce the benefit.
The comparator can change the result substantially. A low-cost Holter monitor may appear attractive, but its short recording window can miss infrequent events. Repeated patch monitors may accumulate costs and inconvenience while still failing to capture a diagnosis. Emergency department visits and inpatient telemetry can be expensive, especially when they do not produce a definitive explanation. A fair analysis should compare complete care pathways rather than the acquisition price of one device.
Time horizon is another major determinant. A short study may undervalue an ILR because implantation costs occur immediately while avoided injuries, admissions, or strokes occur later. A long horizon can better capture these effects, but it also introduces uncertainty about mortality, competing frailty, adherence, and changes in treatment. Discounting future costs and health outcomes should follow the relevant health-economic standards in the jurisdiction being studied.
Designing A Practical Patient Selection Strategy
A cost-effective service should use a structured pathway before implantation. Initial evaluation generally includes history from witnesses or caregivers, orthostatic measurements, medication review, physical examination, a 12-lead ECG, and targeted cardiac testing. Reversible causes such as hypotension, dehydration, hypoglycemia, sedative use, or environmental hazards should be addressed rather than replaced by rhythm monitoring.
External monitoring remains reasonable when symptoms occur frequently enough to be captured. An ILR becomes more attractive when events are separated by weeks or months, activation is unreliable, or the consequences of a missed diagnosis are serious. Shared decision-making should cover the minor procedural risks, wound care, remote monitoring, possible incidental findings, and the likelihood that the device may not explain every fall.
Patient selection may require adaptation for special populations. Adults with congenital heart disease can have complex anatomy, conduction abnormalities, and arrhythmia substrates; the principles in this adult congenital guidance help illustrate why a generic falls algorithm may be inadequate. Frailty, cognitive impairment, anticoagulant use, and limited life expectancy should be incorporated into both clinical decisions and the economic model.
Recommendations For Better Economic Studies
Evidence will be more useful when studies report clinical relevance alongside detection rates. Researchers and clinical programs should consider the following priorities:
- Define unexplained falls carefully and separate probable syncope, near-syncope, and clearly accidental events.
- Compare the ILR with realistic monitoring and care pathways, including repeated emergency assessment and external monitors.
- Measure actionable diagnoses, treatment changes, recurrent falls, injuries, admissions, QALYs, and patient-reported confidence.
- Conduct sensitivity analyses for device cost, monitoring duration, arrhythmia prevalence, treatment uptake, and competing mortality.
- Report results by age, frailty, structural heart disease, ECG risk markers, and event frequency.
Budget impact should complement cost per QALY. A monitoring program may be cost-effective over several years yet require substantial upfront investment in implantation, remote review, staffing, and follow-up capacity. Health systems should estimate the number of eligible patients, expected procedure volume, alert burden, and availability of pacing or electrophysiology services.
Translating Value Into Clinical Practice
The most defensible use of an ILR in unexplained falls is targeted rather than indiscriminate. Patients with recurrent, injurious, or unexplained events and a credible possibility of intermittent arrhythmia are more likely to gain clinical and economic benefit than patients with an isolated, clearly mechanical fall. The decision should be revisited when new symptoms, ECG findings, or changes in functional status alter the probability of cardiac disease.
For researchers, the next step is to build transparent models from prospective diagnostic and outcome data, with assumptions that clinicians can inspect and test. For arrhythmia services, implementation should pair patient selection with rapid review of alerts and a predefined response to bradycardia, atrial fibrillation, and tachyarrhythmia. Clinicians and investigators can use the Journal of Arrhythmia’s research and educational resources to refine monitoring pathways, evaluate local costs, and connect rhythm findings with meaningful patient outcomes.